Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
18.26
-0.68 (-3.59%)
At close: Oct 23, 2026, 4:00 PM EDT
18.36
+0.10 (0.55%)
Pre-market: Oct 26, 2026, 8:09 AM EDT
Vor Biopharma Employees
Vor Biopharma had 76 employees as of December 31, 2025. The number of employees decreased by 83 or 52.20% compared to the previous year. That makes Vor Biopharma the 33,090th largest employer in the world and 4,325th in the United States.
Employees
76
Change (1Y)
-83
Growth (1Y)
-52.20%
Revenue / Employee
n/a
Profits / Employee
$8,260,289
Market Cap
1.08B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 76 | -83 | -52.20% |
| Sep 30, 2025 | 154 | -5 | -3.14% |
| Jun 30, 2025 | 154 | - | - |
| Dec 31, 2024 | 159 | -9 | -5.36% |
| Dec 31, 2023 | 168 | 35 | 26.32% |
| Dec 31, 2022 | 133 | -2 | -1.48% |
| Dec 31, 2021 | 135 | 47 | 53.41% |
| Sep 30, 2021 | 122 | 52 | 74.29% |
| Jun 30, 2021 | 109 | 39 | 55.71% |
| Mar 31, 2021 | 92 | 22 | 31.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 704 |
| MannKind | 592 |
| Replimune Group | 465 |
| MoonLake Immunotherapeutics | 130 |
| Janux Therapeutics | 113 |
| Bicara Therapeutics | 103 |
| ArriVent BioPharma | 77 |
| Savara | 70 |
VOR News
- 3 days ago - Vor Bio says its experimental drug slowed loss of kidney function in late-stage study - Reuters
- 3 days ago - Vor Bio’s telitacicept meets primary endpoint in Phase 3 kidney trial - TheFly
- 3 days ago - Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy - GlobeNewsWire
- 5 days ago - Vor Bio initiated with an Outperform at William Blair - TheFly
- 20 days ago - Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - Vor Bio announces new post hoc analysis from Phase 3 trial on telitacicept - TheFly
- 27 days ago - Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis - GlobeNewsWire
- 4 weeks ago - Vor Biopharma Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts